Low Density Lipoprotein MDA Modified

Product Description

Low Density Lipoprotein MDA Modified
Catalog number: B2012263
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 100 ug
Molecular Weight or Concentration: 1 mg/mL
Supplied as: Liquid
Applications: molecular tool for various biochemical applications
Storage: -20C
Keywords: MDA modified LDL
Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

References:
1: Tikhaze AK, Domogatsky SP, Lankin VZ. [Elimination kinetics of carbonyl-modified low density lipoproteins from bloodstream] Biomed Khim. 2020 Nov;66(6):437-443.
2: Yokoi M, Ito T, Fujita H, Sugiura T, Seo Y, Ohte N. Increased Serum Malondialdehyde-Modified Low-Density Lipoprotein and Coronary Angiographic Progression After Drug-Eluting Stent Implantation in Patients With Stable Angina Circ J. 2020 Sep 25;84(10):1837-1845.
3: Takamura TA, Tsuchiya T, Oda M, Watanabe M, Saito R, Sato-Ishida R, Akao H, Kawai Y, Kitayama M, Kajinami K. Circulating malondialdehyde-modified low-density lipoprotein (MDA-LDL) as a novel predictor of clinical outcome after endovascular therapy in patients with peripheral artery disease (PAD) Atherosclerosis. 2017 Aug;263:192-197.
4: Ito T, Fujita H, Tani T, Sugiura T, Ohte N. Increased circulating malondialdehyde-modified low-density lipoprotein levels in patients with ergonovine-induced coronary artery spasm Ito T, Fujita H, Tani T, Sugiura T, Ohte N.
5: Ohira M, Yamaguchi T, Saiki A, Ban N, Kawana H, Nagayama D, Nagumo A, Murano T, Shirai K, Tatsuno I. Metformin reduces circulating malondialdehyde-modified low-density lipoprotein in type 2 diabetes mellitus Clin Invest Med. 2014 Aug 1;37(4):E243-51.
6: Amioka N, Miyoshi T, Otsuka H, Yamada D, Takaishi A, Ueeda M, Hirohata S, Ito H. Serum malondialdehyde-modified low-density lipoprotein levels on admission predict prognosis in patients with acute coronary syndrome undergoing percutaneous coronary intervention J Cardiol. 2019 Sep;74(3):258-266.
7: Hiraya D, Sato A, Hoshi T, Sakai S, Watabe H, Ieda M. Additional Effect of Coronary High-Intensity Plaque on T1-Weighted Magnetic Resonance Imaging With Circulating Malondialdehyde-Modified Low-Density Lipoprotein on Cardiac Events Circ J. 2021 Oct 25;85(11):2032-2039.
8: Moriyama K. The Association between the Triglyceride to High-density Lipoprotein Cholesterol Ratio and Low-density Lipoprotein Subclasses Intern Med. 2020 Nov 1;59(21):2661-2669.
9: Turunen SP, Kummu O, Wang C, Harila K, Mattila R, Sahlman M, Pussinen PJ, Hörkkö S. Immunization with malondialdehyde-modified low-density lipoprotein (LDL) reduces atherosclerosis in LDL receptor-deficient mice challenged with Porphyromonas gingivalis Innate Immun. 2015 May;21(4):370-85.
10: Ito T, Ichihashi T, Fujita H, Sugiura T, Ohte N. Impact of malondialdehyde-modified low-density lipoprotein on coronary plaque vulnerability in patients not receiving lipid-lowering therapy: a whole coronary analysis with multislice-computed tomography Heart Vessels. 2018 Apr;33(4):351-357.

Products Related to Low Density Lipoprotein MDA Modified can be found at Proteins